Study of an injection for severe acute pancreatitis
Part of Digestive system clinical trials.
This trial tests an investigational medicine called SGC001 given as an injection to people with severe acute pancreatitis, a serious inflammation of the pancreas. The study aims to see if the drug is safe and helpful, and to gather early information on how it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of acute pancreatitis (inflammation of the pancreas) and be at risk for a severe case.
- Your doctor must be able to tell roughly when your stomach pain started.
- You must not have had an ERCP (a bile duct procedure) in the last week, and you must not need immediate emergency procedures.
- You must not have other serious health conditions (like heart, lung, kidney, or immune diseases) or a recent history of cancer.
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding and must agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single injection of a new drug called RABI-767, given through a thin tube during an endoscopic ultrasound (EUS), to see if it can help people with severe acute pancreatitis. The drug is meant to reduce inflammation and prevent complications.
This trial tests infliximab (an anti-inflammatory medicine) versus placebo to see if it improves outcomes in adults with newly diagnosed acute pancreatitis. It is designed for treatment to start within 36 hours of hospital admission.
This trial tests whether taking a probiotic called Bifidobacterium longum can help people with acute pancreatitis recover better. The study compares the probiotic against a placebo (a pill with no active ingredient) to see if it reduces inflammation and complications.
This study looks at how gut bacteria change during acute pancreatitis and whether analyzing them can help predict how severe the condition will become. It may lead to better treatments and faster recovery.
This study looks at specific blood “immune” signatures and how they relate to outcomes in people with acute pancreatitis. If you enroll early, it may help doctors better predict how the illness will go and identify who might need more care.
This trial tests whether taking indomethacin (an anti-inflammatory medicine) early can improve outcomes in people with acute pancreatitis. You might be eligible if your pancreatitis is diagnosed soon and you meet specific lab, imaging, and safety requirements.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.